Citigroup lowers its rating on Stryker SYK as preliminary 4th quarter results provide a disappointing outlook.
Citigroup says, "SYK's 4Q11 sales of $2.2B (11.0%) is only about $5-10MM below our forecast but the mix was worse in Recon which only grew 0.5% organic vs. 6-7% the prior two quarters. This suggests: 1) the hip and knee markets overall are not likely to have shown much improvement in 4Q11 and 2) SYK lost share, primarily in Hips. In contrast, we expected SYK to be in share gain mode for both Hips and Knees."
SYK closed at $53.02 per share on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in